Congratulations to Astrocyte Pharmaceuticals Inc. who began their first in-human Phase 1 clinical study today for their new cerebroprotective therapeutic AST-004! AST-004 is being evaluated as a novel treatment for stroke and traumatic brain injury (TBI) victims. Their study will evaluate the safety, tolerability and pharmacokinetic profile of AST-004 in up to 52 healthy normal human subjects. MTEC is proud to have helped the U.S. Army Medical Research and Development Command (USAMRDC) in sponsoring the advancement of this novel therapeutic. We eagerly await the results of this study and wish all of the hard working scientists at Astrocyte Pharmaceuticals the best of luck.

A full press release can be found here.